Scarica l'app Stockscreener
9.93
3.76%
0.36
Precedente Chiudi:
$9.57
Aprire:
$9.67
Volume 24 ore:
1.70M
Relative Volume:
1.04
Capitalizzazione di mercato:
$881.53M
Reddito:
$71.64M
Utile/perdita netta:
$-294.57M
Rapporto P/E:
-2.9659
EPS:
-3.348
Flusso di cassa netto:
$-84.46M
1 W Prestazione:
+12.08%
1M Prestazione:
+7.93%
6M Prestazione:
+0.81%
1 anno Prestazione:
+63.86%
Intervallo 1D:
$9.55
$9.98
Intervallo di 1 settimana:
$8.84
$9.98
Portata 52W:
$5.45
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.93 | 881.53M | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Iniziato | Lake Street | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Neutral |
| 2025-02-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-14 | Downgrade | Stifel | Buy → Hold |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-08-11 | Iniziato | BofA Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-05-17 | Iniziato | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Iniziato | Jefferies | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-11-09 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-13 | Ripresa | Leerink Partners | Outperform |
| 2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-30 | Iniziato | Oppenheimer | Outperform |
| 2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
Understanding the Setup: (KURA) and Scalable Risk - Stock Traders Daily
[144] Kura Oncology, Inc. SEC Filing - Stock Titan
Kura Oncology Inc (KURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kura Oncology Inc (KURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kura Oncology Inc (KURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kura Oncology Inc (KURA) Institutional Confidence - TradingKey
Kura Oncology Inc (KURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kura Oncology Inc (KURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kura Oncology Inc (KURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kura Oncology Inc (KURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
KURA Reiterates by Citizens -- Price Target Maintained at $24.00 - GuruFocus
Citizens reiterates Kura Oncology stock rating on strong trial data - Investing.com
Citizens reiterates Kura Oncology stock rating on strong trial data By Investing.com - Investing.com Canada
Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Kura Oncology, Inc. (KURA) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
KURA: Ziftomenib plus 7+3 shows high response and survival rates in AML, supporting phase III trials - TradingView
KURA: Ziftomenib plus 7+3 shows high, durable remission and survival in AML, supporting phase III trials - TradingView
Kura Oncology Inc EHA Investor Event Transcript - GuruFocus
Number of shareholders of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results For Ziftomenib And 7+3 Combination In Newly Diagnosed AML - marketscreener.com
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term - GlobeNewswire
Kura Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
Why Did KURA Stock Jump 13% In Pre-Market Today? - Stocktwits
The Technical Signals Behind (KURA) That Institutions Follow - Stock Traders Daily
How The Kura Oncology (KURA) Investment Narrative Is Evolving Without New Analyst Revisions - Yahoo Finance
Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for DarlifarnibSlideshow - Seeking Alpha
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $23 to $40 - Moomoo
Kura Oncology Advances Targeted Combo in Tough Head and Neck Cancer - TipRanks
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Analysts’ Top Healthcare Picks: Kura Oncology (KURA), Align Tech (ALGN) - The Globe and Mail
UBS Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Director at Kura Oncology (NASDAQ: KURA) receives 35,000-share option grant - Stock Titan
Kura Oncology (KURA) director receives grant of 35,000 stock options at $8.77 - Stock Titan
Kura Oncology (KURA) awards director stock options at $8.77 strike - Stock Titan
Kura Oncology (KURA) director receives 35,000 options at $8.77 strike price - Stock Titan
Kura Oncology (KURA) director Carol Schafer granted 35,000 stock options - Stock Titan
Director Mary Szela awarded 35,000 Kura Oncology (KURA) options - Stock Titan
Kura Oncology (KURA) director receives option grant for 35,000 shares at $8.77 - Stock Titan
[8-K] Kura Oncology, Inc. Reports Material Event - Stock Titan
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $28 to $40 - Moomoo
Cantor Fitzgerald reiterates Kura Oncology stock Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Kura Oncology stock Overweight rating - Investing.com
Barclays Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Citizens reiterates Kura Oncology stock rating on FIT-001 data By Investing.com - Investing.com South Africa
Citizens reiterates Kura Oncology stock rating on FIT-001 data - Investing.com
Kura Oncology Inc ASCO Investor Event Transcript - GuruFocus
KURA Highlights Promising Data for Darlifarnib in KRAS-Mutant Ca - GuruFocus
Kura Oncology reports phase 1a data for cancer drug combination - Investing.com UK
Kura Oncology reports phase 1a data for cancer drug combination By Investing.com - Investing.com Australia
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):